Analyzing the sizes and interactions of biomolecules using advanced ultracentrifugation techniques
Official title: Beckman Optima A/I Analytical Ultracentrifuge (AUC)
Funded at University of Notre Dame · NIH-11102201 · Data updated 2026-11-12
This study is using a special machine to look closely at the sizes and shapes of important molecules like proteins and DNA, helping scientists understand how they work and change in different situations, all while keeping the samples safe for more tests later.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Notre Dame NIH-funded |
| Lab location | 1 site (Notre Dame, United States) |
| Project start | May 15, 2025 |
| Project end | May 14, 2026 |
| Funding year | 2025 |
| Award (this year) | $350,000 |
| NIH project number | 1S10OD038334-01 |
| Project ID | NIH-11102201 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation or benefit from this research include individuals under 18 years of age who are involved in studies related to biomolecular functions or treatments.
✕Less likely to help
Patients who are over 18 years old or those not involved in biomolecular research may not receive direct benefits from this research.
What this research studies
This research focuses on using a state-of-the-art analytical ultracentrifuge to study the sizes, shapes, and interactions of biomolecules such as proteins and nucleic acids. By measuring how these molecules behave in a solution, researchers can gain insights into their biological functions and how they change under different conditions. The ultracentrifuge allows for precise measurements without damaging the samples, making it possible to conduct further analyses on the same material. This advanced technology aims to enhance the capabilities of scientists at the University of Notre Dame in their investigations of complex biological processes.
Why it matters
Potential benefit: If successful, this research could lead to a better understanding of biomolecular interactions, which may improve the development of targeted therapies and diagnostics.
How similar studies have gone: Previous research utilizing analytical ultracentrifugation has shown success in characterizing biomolecular interactions, indicating that this approach is well-established and effective.
Where this research is happening
-
University of Notre Dame
Notre Dame, United States Active
Researchers
- Principal investigator: Mobashery, Shahriar — University of Notre Dame
- Study coordinator: Mobashery, Shahriar
Related research
Other NIH-funded projects on the same topics.
-
Designer covalent blockers to stop IgE-driven allergic reactions
A new approach aims to block IgE antibodies that trigger allergic reactions in people with allergic asthma, potentially reducing severe symptoms without broad immune suppression.
-
A life-course view of how early adversity shapes health as people grow up
This NIH grant looks at how tough experiences in childhood and adolescence affect health and aging later in life, using data from people and animal studies to understand why some outcomes are worse and how social factors can help.
-
How a simple, evidence-based approach helps mothers and kids in Peru feel better
A study tests a flexible, lay-delivered mental-health program called CETA for mothers of young children in Lima to improve family well-being.
-
Open-Source tools to test conversational AI for dementia care
A multilingual AI benchmarking project aims to help improve chatbots and virtual assistants used in Alzheimer’s and related dementias, with open tools and datasets for researchers and clinicians.
-
Decoding how human CD8+ T cells recognize donor HLA in transplant rejection
This project studies why certain T cells attack transplanted kidneys, with the goal of understanding which cells drive acute rejection and how they recognize donor HLA.
-
Targeted antibody-guided nanoparticles to treat CMV infection
A new treatment approach combines CMV-targeting antibodies with drug-loaded nanoparticles to deliver antiviral medicine directly to infected cells, aiming to improve efficacy and reduce side effects for people with CMV infection.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.